Skip to main content
OpenTrials
Completed

NCT Number: NCT00182221

Safety of a Diagnostic Strategy With D-Dimer Testing for PE

To determine whether D-Dimer testing, using the MDA D-Dimer assay, can be used to simplify the diagnostic process for pulmonary embolism (PE). This will be assessed by performing a cohort study in 1000 patients with suspected PE.

To ascertain if an MDA D-Dimer result of less than 0.75 ug/mL FEU obviates the need for further testing and therapy in patients with suspected PE.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Embolism Embolism and Thrombosis Lung Diseases Pulmonary Embolism Respiratory Tract Diseases Thromboembolism Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hamilton Health Sciences, General, Hamilton, Ontario, Canada

Loading trial locations.

About this study

Prospective cohort study of 1000 patients in which those with a negative D-Dimer result undergo no further testing and are followed for 3 months for venous thromboembolism. Patients with a positive D-Dimer undergo standardized testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • Suspected PE

Exclusion criteria

  • Treatment with full-dose anticoagulants for 24 hours or more OR an ongoing requirement for anticoagulants
  • Other tests for PE performed prior to eligibility assessment (e.g.other D-Dimer, V/Q scan, pulmonary angiogram, spiral CT, compression ultrasound, venogram).
  • Cardiorespiratory instability requiring immediate performance of other tests to diagnose or exclude PE (i.e. inability to wait 30-60 minutes for MDA D-Dimer result)
  • Comorbid condition limiting survival to less than three months
  • Patient has been asymptomatic for seven days prior to presentation
  • Current pregnancy
  • Contraindication to contrast (e.g., allergy, renal failure).
  • Geographic in accessibility which precludes follow-up
  • Presence of central venous catheter (permanent or temporary, including PICC line) at the time of eligibility assessment

Treatment and study plan

MDA D-Dimer Testing

Procedure

Primary outcomes

  1. Venousthromboembolism

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Collaborators

  • Heart and Stroke Foundation of Ontario

Registry information

Official study title

A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer Testing in Patients With Suspected Pulmonary Embolism

Important dates

Study start
2003
Primary completion
2008
Study completion
2008
First posted
Sep 16, 2005
Registry last updated
Mar 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.